Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.60    -0.10 (-3.70%)
Bid:
2.60
Ask:
2.70
Spread: 0.10 (3.846%)
Market Cap: £2.78m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Market Update

19 Jul 2021 07:00

RNS Number : 6352F
Litigation Capital Management Ltd
19 July 2021
 

19 July 2021

 

Litigation Capital Management Limited

("LCM" or "the Company")

 

Market Update

 

 

Litigation Capital Management Limited (AIM:LIT), a leading international alternate asset manager of disputes financing solutions, is pleased to provide a market update for the year ended 30 June 2021 (FY21).

 

 

·

LCM's 10 year track record remains robust with 10 year portfolio ROIC as at 30 June 2021 of 153% and cumulative portfolio IRR of 78%

·

The Global Alternative Returns Fund (GAR) is currently 76% committed achieved in 15 months, versus an investment target period of 24 months. Overall capital commitment of US$115m of US$150m. The second fund is progressing well with a close targeted for Q3 of this calendar year

·

Applications increased 10%, with 572 applications received during FY21

·

Conversion into active investments was also consistent at 3%, with an increase in high profile quality investments requiring increased resource allocation. This conversion rate demonstrates LCM's discipline and consistency in applying its rigorous due diligence in investment selection

·

Whilst all other scale metrics showed an increase on the year prior, the level of commitments was down due to our due diligence and investment selection taking longer due to COVID. This increased due diligence time recognises a general slow-down in all sectors of legal services consequent upon COVID

·

Total portfolio capital commitment of $181m comprises $105m of Direct investments alongside a further $76m of Fund co-investment maintaining a diverse portfolio of investments

 

Patrick Moloney, CEO of LCM, commented: "LCM and our team have performed very well in what has been a tough and disrupted year. The GAR Fund is now over 75% committed, and we are making significant progress on the second fund with strong support from both existing and new investors. Notwithstanding some disruption to global justice systems, LCM's portfolio of disputes continues to mature.

"We are pleased to have achieved a significant resolution of an investment close to the end of the financial year which has generated strong revenue and exceptional performance metrics.

"We look forward to the coming year with optimism and an expectation that global economic conditions will be very conducive to growth.

 

Direct Investment

LCM's direct investments fall into two categories:

· Direct Balance sheet investments 100% funded by LCM; and

· Co-Investment funding alongside the Fund

LCM manages a direct investments portfolio with a capital commitment of $105m, which now comprises 30 separate investments including 8 investments in our acquisition strategy. Our Corporate Portfolios continue to achieve resolutions with consistent metrics.

Our portfolio of direct investments is progressing as anticipated, with our most recently announced resolution achieving an IRR of 121% and a ROIC of 313%.

Asset Management  

LCM has now committed 76% of the US$150m Fund across 22 projects while maintaining diversity across commercial litigation, insolvency disputes, class actions and arbitration.

All investors in Fund I have expressed a strong interest to participate in Fund II which is targeted at a size of US$300m. This demonstrates the strength of the relationships developed since launching Fund I in March 2020.

Application conversions were marginally lower at 3% as the restrictions imposed in response to the COVID pandemic continued across the globe. This expected lowering in conversion reflects LCM's rigorous due diligence adapting to market conditions particularly in the area of recovery. Despite the challenges faced and the limited client interaction, LCM added a number of high quality and high profile investments to its portfolio during the period. Notwithstanding these challenges, LCM maintained its rigorous investment selection process, ensuring the future performance of our portfolio is preserved and delivers in line with our track record.

 

Strategic Alliances

LCM's Strategic Alliances continue to generate applications and, as restrictions in the UK start to lift, we expect to see this increase as we resume business meetings and develop the investment selection process with the teams we work with.

The accompanying market update presentation is available on LCM's website:

https://www.lcmfinance.com/shareholders/investor-presentations-results/

 

 

Enquiries

 

Litigation Capital Management

c/o Alma PR 

Patrick Moloney, Chief Executive Officer

 

 

 

 

 

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam

 

 

 

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

 

 

 

 

 

Alma PR

Tel: 020 3405 0205

Justine James

Susie Hudson

Kieran Breheny

Molly Gretton

LCM@almapr.co.uk

 

 

 

 

NOTES TO EDITORS

 

Litigation Capital Management (LCM) is a global provider of disputes finance. LCM provides capital and risk manager services into the disputes market including insolvency, commercial disputes, arbitral disputes, class actions and corporate portfolios. LCM operates two distinct business models: direct balance sheet investments and asset management. Under those business models, LCM pursues three investment strategies: single-case funding, corporate portfolio funding and the acquisition of claims.

LCM has an unparalleled track record, driven by effective project selection, active project management and robust risk management.

 

Current headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

www.lcmfinance.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFFSIUEFSEIW
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.